BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 16999858)

  • 21. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
    Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
    Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
    Bamias A; Bamia C; Karadimou A; Soupos N; Zagouri F; Rodolakis A; Haidopoulos D; Vlahos G; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2011; 81(5-6):365-71. PubMed ID: 22248920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
    J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.
    Young RC
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):8-10. PubMed ID: 10952120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
    De Vos FY; Bos AM; Schaapveld M; de Swart CA; de Graaf H; van der Zee AG; Boezen HM; de Vries EG; Willemse PH
    Gynecol Oncol; 2005 Apr; 97(1):60-7. PubMed ID: 15790438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of progression-free interval in patients with ovarian cancer treated by first-line chemotherapy with paclitaxel and carboplatin].
    Lehoczky O; Pulay T
    Magy Onkol; 2005; 49(4):315-8. PubMed ID: 16518475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
    Sehouli J; Stengel D; Mustea A; Camara O; Keil E; Elling D; Ledwon P; Christiansen B; Klare P; Gebauer G; Schwarz M; Lichtenegger W;
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):243-50. PubMed ID: 17393164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix.
    Lee MY; Wu HG; Kim K; Ha SW; Kim JS; Kim IA; Lee HP
    Gynecol Oncol; 2007 Jan; 104(1):95-9. PubMed ID: 16996117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.
    Bolis G; Scarfone G; Polverino G; Raspagliesi F; Tateo S; Richiardi G; Melpignano M; Franchi M; Mangili G; Presti M; Villa A; Conta E; Guarnerio P; Cipriani S; Parazzini F
    J Clin Oncol; 2004 Feb; 22(4):686-90. PubMed ID: 14966092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
    Dinniwell R; Lock M; Pintilie M; Fyles A; Laframboise S; Depetrillo D; Levin W; Manchul L; Murphy J; Oza A; Rosen B; Sturgeon J; Milosevic M
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):104-10. PubMed ID: 15850909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
    Gemignani ML; Hensley ML; Cohen R; Venkatraman E; Saigo PE; Barakat RR
    Gynecol Oncol; 2001 Jan; 80(1):16-20. PubMed ID: 11136563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
    J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
    Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
    Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.